Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine

Janet H. Ford, Tobias Kurth, Amaal J. Starling, David W. Ayer, Linda A. Wietecha, Martha D. Port, Mallikarjuna Rettiganti, Dustin D. Ruff

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Fingerprint Dive into the research topics of 'Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine'. Together they form a unique fingerprint.

Medicine & Life Sciences